The most common side effect is bone marrow suppression. The most common non-hematological adverse effects associated with<unk>  are nausea and vomiting, which are either self-limiting or readily controlled with standard antiemetic therapy. These latter effects are usually mild to moderate (grade 1 to 2). The incidence of severe nausea and vomiting is around 4% each. Patients who have pre-existing or a history of severe vomiting may require antiemetic therapy before initiating<unk>  treatment.<unk>  should be administered in the fasting state, at least one hour before a meal. Antiemetic therapy may be administered before, or following, administration of<unk> .<unk>  is genotoxic, teratogenic and fetotoxic and should not be used during pregnancy. Lactating women should discontinue nursing while receiving the drug because of the risk of secretion into breast milk. One study indicated that women that have taken<unk>  without concomitant fertility preservation measures achieve pregnancy to a lesser rate later in life, but the study was too small to show statistical significance in the hypothesis that<unk>  would confer a risk of female infertility. In male patients,<unk>  can have genotoxic effects. Men are advised not to father a child during or up to six months after treatment and to seek advice on cryoconservation of sperm prior to treatment, because of the possibility of irreversible infertility due to<unk>  therapy. Very rarely<unk>  can cause acute respiratory failure or liver damage.
Temozolomide
Vincristine
Carmustine
Bendamustine
Lomustine
Ifosfamide
Trifluridine
Doxorubicin